Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S1XX
|
|||
| Drug Name |
Deucravacitinib
|
|||
| Synonyms |
BMS-986165
Click to Show/Hide
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0; ICD-9: 696] | Approved | [1] | |
| Psoriasis vulgaris [ICD-11: EA90; ICD-10: L40] | Phase 3 | [2] | ||
| Company |
Bristol Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H22N8O3
|
|||
| Canonical SMILES |
CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
|
|||
| InChI |
1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
|
|||
| InChIKey |
BZZKEPGENYLQSC-FIBGUPNXSA-N
|
|||
| CAS Number |
CAS 1609392-27-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214958. | |||
| REF 2 | ClinicalTrials.gov (NCT04036435) Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.